Matt Holdren

Matt Holdren has worked in the pharmaceutical industry since 1997. Theirwork experience includes roles at ZymoGenetics, Bristol-Myers Squibb, Genentech, Tenaya Therapeutics, and Lycia Therapeutics. At ZymoGenetics, they were a Research Associate in Pharmacology from 1997 to 2006, and a Senior Scientist in Toxicology from 2006 to 2011. At Bristol-Myers Squibb, they were a Senior Research Investigator in Drug Safety Evaluation from 2011 to 2013. At Genentech, they held the positions of Project Toxicologist, Associate Director, Director, and Senior Director from 2013 to 2021. Most recently, they have been the Vice President of Preclinical Development at Tenaya Therapeutics since 2021, and they are currently the Vice President of Nonclinical Development at Lycia Therapeutics since 2022.

Matt Holdren received a Doctor of Philosophy (Ph.D.) from the University of Washington and a Bachelor of Science (B.S.) from the same institution. In 2012, they also obtained a Diplomate from the American Board of Toxicology, Inc.